Merck & Co Inc

NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024

MRK Articles

After Pfizer and Merck released their most recent earnings reports last week, analysts weighed in on both of these pharmaceutical giants.
Merck reported mixed fourth-quarter financial results before the markets opened Wednesday.
24/7 Wall St. has put together a preview of the three Dow Jones Industrial Average companies that are reporting their quarterly results this week.
Some of the Dow stocks that are down in 2016 haven't even reported earnings. This is the market bracing for bad news, but one cannot wonder if that means that the earnings bar is being lowered...
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
January 27, 2016: Markets opened lower on Wednesday, but a brief morning sojourn into positive territory only lasted until the FOMC announcement in the early after. Traders saw their shadows and...
Wednesday's top analyst calls include Apple, AT&T, DuPont, Fitbit, Huntington Bancshares, McDonald's, Merck, Newmont Mining and Sprint.
Affimed shares rose on Monday following the announcement of a collaboration in immuno-oncology with biotech giant Merck.
Investors need to keep in mind that the downside target for the Dow Jones Industrial Average will sink lower if the market keeps drifting south.
A bull market interrupted is how many investors likely feel at the start of 2016. These are the seven Dow stocks that will be needed to drive the Dow higher in 2016.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case for each in 2016.
Dogs of the Dow is a dividend strategy for investors to buy what are either "cheap" or "beaten up" Dow stocks. Unfortunately, 2015 was an awful year for the members of the Dogs of the Dow.
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and...